MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 

Location: Categories / Finance & Investment / Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.
Old Articles: <Older 28961-28970 Newer>
The Motley Fool
February 29, 2008
Rich Smith
Foolish Forecast: AeroVironment's Pre-Flight Reality Check In its first year as a public company, AeroVironment turned in results that beat expectations in every single quarter. But can this high-tech model-airplane maker repeat the feat in year two? mark for My Articles 155 similar articles
The Motley Fool
February 29, 2008
Toby Shute
URS' Ursine Outlook For this contractor, the weak economy is definitely a factor, possibly putting a damper on infrastructure spending over the next year or two. mark for My Articles 11 similar articles
The Motley Fool
February 29, 2008
Brian Lawler
NeurogesX Gets a Painful Kick in the Pants NeurogesX's lead drug fails in clinical testing. mark for My Articles 54 similar articles
The Motley Fool
February 29, 2008
Sham Gad
Housing Stocks Beating Mr. Market The housing industry is actually one of the best-performing industries so far in 2008. (Imagine that.) mark for My Articles 365 similar articles
The Motley Fool
February 29, 2008
Alyce Lomax
Hit the Deck(ers)! Deckers' fourth-quarter net income increased 189%, but is Deckers Outdoors' UGG brand soon to be left on the wayside, like many passing fads -- and more importantly, when? mark for My Articles 96 similar articles
The Motley Fool
February 29, 2008
Brian Orelli
Barred by Debt The picture continues to look bleak at Barr Labs, due to debt taken on to acquire Pliva in 2006. mark for My Articles 206 similar articles
The Motley Fool
February 29, 2008
Anders Bylund
Netflix Pursues a World of Growth Deep in an SEC 10-K filing, DVD renter Netflix reveals its plans for world domination. mark for My Articles 848 similar articles
The Motley Fool
February 29, 2008
Brian Lawler
Regeneron's Orphan Charms the FDA Regeneron Pharmaceuticals receives marketing approval from the FDA for a treatment that targets a very rare inflammatory disease. mark for My Articles 58 similar articles
The Motley Fool
February 29, 2008
Jason Ramage
A Grilling at Famous Dave's Opening new restaurants really hurt the bottom line for the fourth quarter at Famous Dave's. mark for My Articles 205 similar articles
The Motley Fool
February 29, 2008
Anders Bylund
Viacom Rocks Out, Robot-Style Entertainment production powerhouse Viacom cites the writers strike as one of the three major reasons behind its fine performance in the fourth quarter. mark for My Articles 334 similar articles
<Older 28961-28970 Newer>    Return to current articles.